Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.
CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.
Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.
May 1, 2013 – The deadline for applying for one of the 2013 Sultan Bin Khalifa International Thalassemia Awards,established by H.H. Dr. Sheikh Sultan Bin Khalifa Al Nahyan in partnership with the Thalassaemia International Federation, is June 15. The Awards are intended to recognize outstanding contributions in thalassemia by medical professionals, researchers, patients, parents and organizations. […]
The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to support ongoing clinical research projects in thalassemia. The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the […]
The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and Gene Therapy to advance a cure for thalassemia. The purpose of this initiative is to speed the application of recent translational advances in cell and gene therapy to clinical trials. Both phase I (safety) and […]
January 28, 2013 – Acceleron, a biopharmaceutical company based in Cambridge, Massahusetts, in collaboration with Summit, New Jersey-based pharmaceutical partner Celgene Corporation, is developing two programs, sotatercept (formerly called ACE-011) and ACE-536, for the treatment of beta-thalassemia. Sotatercept and ACE-536 are biologic drugs that increase hemoglobin and red blood cells levels by promoting the maturation […]
January 23, 2013 – From an FDA press release: The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). NTDT is a milder form of thalassemia that does […]
January 10, 2013 – CAF has learned that the first U.S.-based clinical trial in gene therapy for beta-thalassemia has begun treating trial participants. The Phase 1 study, the official title of which is “ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene,” is […]
December 1, 2010 – A study published ahead of print in the journal Haematologica presents data indicating that the oral chelator deferasirox (Exjade) is effective at removing iron from the hearts of patients with thalassemia. The study (“Continued improvement in myocardial T2* over 2 years of deferasirox treatment in β-thalassemia major patients with cardiac iron […]
